Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma
Status:
Unknown status
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
Basal like breast carcinoma is a Her2, estrogen receptor (ER) progesterone receptor (PR)
negative breast cancer. It is notable for the high level of epidermal growth factor receptor
(EGFR) expression in this tumor subtype .
Thus the investigators wanted to combine the use of anti EGFR therapy in the form of Erbitux
(cetuximab) with the widely used weekly taxol chemotherapy for the treatment of these women.
This is a small phase I/II study.